Using the AGP to Standardize Glucose Reporting

Slides:

Advertisements

Similar presentations

Canadian Diabetes Assocaition Clinical Practice Guidelines Pharmacotherapy in Type 1 Diabetes Chapter 12 Angela McGibbon, Cindy Richardson, Cheri Hernandez,

Advertisements

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes Featured Article: Michaela Diamant, Michael A.

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

Diabetes Technology Update

Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 3 of 3.

Use of The FreeStyle Navigator TM Continuous Glucose Monitoring System in Children on Glargine- based Multiple Daily Injection Therapy Stuart Weinzimer.

Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.

Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes A pilot, randomized,

Dr Zaranyika MBChB(Hons) UZ, MPH, FCP SA Department of Medicine UZ-CHS

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

What's New in Basal Insulin for Diabetes

Insulin glargine compared with premixed insulin for management of insulin-naïve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the.

Type 1 Diabetes: Meters, Pumps, and Transitions to Adulthood

Short-, Intermediate-, Long-Acting Insulins

Applying Data to Practice

Diabetes and Risk of CV Outcomes

Lifestyle and Professional CGM

Special Consideration in Insulin Therapy

Faster-Acting Insulins

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

New Patient-Friendly Options for Managing Insulin Dosing

The Next Generation of Basal Insulins

Modern Strategies for Basal Insulin Use in T2D

Utilizing New Technologies and Insulins for a Tighter Grip on PPG

What Comes Second?.

How Early Should Basal Insulin Be Used in T2D Management?

Best Practices in Advanced Glucose Monitoring

SGLT2 Inhibitors in the Modern Era: Why and Where?

Examining CV Effects of Basal Insulin Therapy

Updates to Managing Diabetes in the Long-Term Care Setting

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Emerging Basal Insulins for Diabetes

Faster-Acting Insulins

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Novel Basal Insulin Formulations in the Modern Era of T2D Management

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Simplifying Insulin Delivery for Better Patient Outcomes in T2D

Predictive Low Glucose Suspend (PLGS)

The Primary Care Guide to New CGM Devices and the AGP

Novel Approaches to T1D Management

Glucose Monitoring: An Evolving Landscape

Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.

Glycemic response to a pizza meal illustrated on a line graph (DexCom Data Manager 2 Software). Glycemic response to a pizza meal illustrated on a line.

T2DM Management.

Better Diabetes Control With Novel Basal Insulins

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Modern Advances in Glucose Monitoring

Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Approach to starting and adjusting insulin in type 2 diabetes.

Dual SGLT1/SGLT2 Inhibition in T1D

Advancements in Glucose Monitoring

Hypoglycemia: The Most Common Barrier to Effective Diabetes Management

Glycemic Management in ESRD and Earlier Stages of CKD

Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial

Hypoglycemia Is BAD.

NP and PA Expert Exchange:

Improving Effective Basal Insulin Use in Clinical Practice

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Are All Novel Insulins Proven to Be Equally Safe?

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

Insulin Delivery Systems Atlanta Diabetes Associates

New Advances in Hybrid Closed-Loop Control of Insulin Therapy

Emerging Basal Insulins for Diabetes

Fresh perspectives ON BASAL Insulins in diabetes care

The Challenge of Insulin Titration

Presentation transcript:

Using the AGP to Standardize Glucose Reporting

Evolution of Glucose Monitoring

There Is a Need for a Standardized Glucose Report

Development of the AGP

HbA1c and Glucose

Standardization of Reporting (With AGP)

The Ambulatory Glucose Profile (AGP) Report

Adoption of the AGP in Modern and Standardized CGM

Interprofessional Care

41-Year-Old Man With T1D and Taking Glargine/Lispro, HbA1c = 6.4%

Nocturnal Hypoglycemia and Glycemic Variability

In T1D, Hypoglycemia Is Extremely Common When HbA1c Levels Are Less Than 7%

52-Year-Old Man With T1D and ESRD and Receiving Peritoneal Dialysis, HbA1c = 6.9%

69-Year-Old With T2D, Taking 20 Units Glargine, 20-30 Units Lispro Before Meals, HbA1c = 6-6.5%

Nocturnal Hypoglycemia

Lipohypertrophy

62-Year-Old Man With T2D, Taking Basal Insulin and Mealtime Insulin, HbA1c = 9.2%

Glycemic Variability

Hypoglycemia After Meals

78-Year-Old Woman With T1D for 52 Years, HbA1c = 8.5%

Nocturnal Hypoglycemia

Follow-Up: Patient Owns CGM (Dexcom G5)

45-Year-Old Man With T1D and Using Insulin Pump, HbA1c = 6.5%

Hypoglycemia All Day Long

Hypoglycemia Unawareness

The AGP Streamlined Report

Closing Comments

Abbreviations